Moreover, high SLUG expression is associated with poor clinical outcomes in human gastric cancer [14], esophageal squamous cell carcinoma [15, 16], colorectal carcinoma [17], lung adenocarcinoma [18], and prostate cancer [19]. Here, SNAI2 is linked to lung adenocarcinoma.